hy-n2155 Search Results


tubuloside a  (MedChemExpress)
94
MedChemExpress tubuloside a
CA upregulated PLIN5 expression and ameliorated renal injury and lipid accumulation in db/db mice. (A) Schematic workflow of the docking-based virtual screening for natural product candidates targeting PLIN5 protein. (B) Chemical structure formula of five candidate products (tetragalloylglucose, cistanoside A, chebulinic acid (CA), tubuloside A, and poliumoside) in 2D conformer. (C) Relative fluorescence intensity of BODIPY among different treatment groups ( n = 3). (D) ORO staining among different treatment groups ( n = 3). (E) Western blot assay showing expression of PLIN5 among different treatment groups and quantitative analyses ( n = 3). (F) Mice were treated daily by oral gavage with CA (10 mg/kg) or the solvent vehicle for 3 weeks and were sacrificed at 20 weeks. (G) Body weight of different groups of mice at week 20. (H) Blood glucose of different groups of mice at week 20. (I) Urinary albumin-to-creatinine ratio (UACR) in different groups of mice. (J) Representative periodic acid–Schiff (PAS) and quantified glomerular sclerosis index staining in glomerulus from renal tissues ( n = 6). (K) Representative BODIPY staining in glomerulus from renal tissues ( n = 6). (L) Western blot assay showing expression of PLIN5 among different treatment groups and quantitative analyses ( n = 6). (M) Representative images and quantification of PLIN5 (red), WT1 (green), and DAPI (blue)-immunofluorescent stained in glomeruli from renal tissues ( n = 6). ns: not significant ( p > 0.05), * p < 0.05, ** p < 0.01, and *** p < 0.001. Five visual fields for each section analyzed.
Tubuloside A, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hy-n2155/Tubuloside+A/pmc13178040-37-8-15
Average 94 stars, based on 1 article reviews
tubuloside a - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

Image Search Results


CA upregulated PLIN5 expression and ameliorated renal injury and lipid accumulation in db/db mice. (A) Schematic workflow of the docking-based virtual screening for natural product candidates targeting PLIN5 protein. (B) Chemical structure formula of five candidate products (tetragalloylglucose, cistanoside A, chebulinic acid (CA), tubuloside A, and poliumoside) in 2D conformer. (C) Relative fluorescence intensity of BODIPY among different treatment groups ( n = 3). (D) ORO staining among different treatment groups ( n = 3). (E) Western blot assay showing expression of PLIN5 among different treatment groups and quantitative analyses ( n = 3). (F) Mice were treated daily by oral gavage with CA (10 mg/kg) or the solvent vehicle for 3 weeks and were sacrificed at 20 weeks. (G) Body weight of different groups of mice at week 20. (H) Blood glucose of different groups of mice at week 20. (I) Urinary albumin-to-creatinine ratio (UACR) in different groups of mice. (J) Representative periodic acid–Schiff (PAS) and quantified glomerular sclerosis index staining in glomerulus from renal tissues ( n = 6). (K) Representative BODIPY staining in glomerulus from renal tissues ( n = 6). (L) Western blot assay showing expression of PLIN5 among different treatment groups and quantitative analyses ( n = 6). (M) Representative images and quantification of PLIN5 (red), WT1 (green), and DAPI (blue)-immunofluorescent stained in glomeruli from renal tissues ( n = 6). ns: not significant ( p > 0.05), * p < 0.05, ** p < 0.01, and *** p < 0.001. Five visual fields for each section analyzed.

Journal: Renal Failure

Article Title: Targeting LRH-1 alleviates diabetes-induced lipotoxicity in podocytes: role of PLIN5-mediated lipid droplet turnover

doi: 10.1080/0886022X.2026.2670806

Figure Lengend Snippet: CA upregulated PLIN5 expression and ameliorated renal injury and lipid accumulation in db/db mice. (A) Schematic workflow of the docking-based virtual screening for natural product candidates targeting PLIN5 protein. (B) Chemical structure formula of five candidate products (tetragalloylglucose, cistanoside A, chebulinic acid (CA), tubuloside A, and poliumoside) in 2D conformer. (C) Relative fluorescence intensity of BODIPY among different treatment groups ( n = 3). (D) ORO staining among different treatment groups ( n = 3). (E) Western blot assay showing expression of PLIN5 among different treatment groups and quantitative analyses ( n = 3). (F) Mice were treated daily by oral gavage with CA (10 mg/kg) or the solvent vehicle for 3 weeks and were sacrificed at 20 weeks. (G) Body weight of different groups of mice at week 20. (H) Blood glucose of different groups of mice at week 20. (I) Urinary albumin-to-creatinine ratio (UACR) in different groups of mice. (J) Representative periodic acid–Schiff (PAS) and quantified glomerular sclerosis index staining in glomerulus from renal tissues ( n = 6). (K) Representative BODIPY staining in glomerulus from renal tissues ( n = 6). (L) Western blot assay showing expression of PLIN5 among different treatment groups and quantitative analyses ( n = 6). (M) Representative images and quantification of PLIN5 (red), WT1 (green), and DAPI (blue)-immunofluorescent stained in glomeruli from renal tissues ( n = 6). ns: not significant ( p > 0.05), * p < 0.05, ** p < 0.01, and *** p < 0.001. Five visual fields for each section analyzed.

Article Snippet: 1,2-Dilauroyl-sn-glycerol-3-phosphocholine (DLPC), tetragalloylglucose, cistanoside A, chebulinic acid (CA), tubuloside A, and poliumoside were purchased from MedChemExpress (Shanghai, China), dissolved in glycolic acid (GC) at 23 °C, and kept at −20 °C.

Techniques: Expressing, Fluorescence, Staining, Western Blot, Solvent